Included support
- +Hospital matching
- +Record review
- +Care coordination
- +Travel support
- +Interpretation support

Autologous hematopoietic stem cell transplantation (ASCT) may be considered when non-Hodgkin lymphoma is sensitive to induction or salvage chemotherapy and has a high risk of relapse, or when consolidation therapy is needed after relapse. The decision is influenced by factors such as pathological su
24-72h
Response window
Approx. $15,000
Treatment fee
Peking Union Medical College Hospital - Beijing - Grade 3A
Ruijin Hospital - Shanghai - Grade 3A
West China Hospital - Chengdu - Grade 3A
Let us coordinate the treatment journey with you.
Autologous hematopoietic stem cell transplantation typically begins with drug mobilization to move hematopoietic stem cells into the peripheral blood; these are then collected using apheresis equipment and cryopreserved. After evaluation, high-dose chemotherapy is administered as preconditioning to reduce the tumor burden and create space for hematopoiesis, followed by reinfusion of the previously stored stem cells. During treatment, blood counts, infection, and organ function are routinely monitored, with blood transfusions, anti-infection measures, and nutritional support provided as needed. The overall goal is to promote hematopoietic reconstitution and a smooth discharge. The above is general health information, not medical advice; specific details are subject to specialist evaluation and hospital protocols.
Autologous hematopoietic stem cell transplantation typically begins with drug mobilization to move hematopoietic stem cells into the peripheral blood; these are then collected using apheresis equipment and cryopreserved. After evaluation, high-dose chemotherapy is administered as preconditioning to reduce the tumor burden and create space for hematopoiesis, followed by reinfusion of the previously stored stem cells. During treatment, blood counts, infection, and organ function are routinely monitored, with blood transfusions, anti-infection measures, and nutritional support provided as needed. The overall goal is to promote hematopoietic reconstitution and a smooth discharge. The above is general health information, not medical advice; specific details are subject to specialist evaluation and hospital protocols.

Including preoperative evaluation, hospitalization, and postoperative follow-up, it is recommended to stay in China for approximately 6–10 weeks; the specific duration depends on bed and examination arrangements and individual recovery.

Tell us about your Non-Hodgkin Lymphoma case and we will help match you with the right hospital, specialist, and travel pathway.